A novel peptide of endothelin family, 31 amino-acid length endothelin in patients with acute myocardial infarction by Oka, Makiko et al.
INTRODUCTION
The peptides of endothelin (ET) family contain
of 21 amino acids with three members, i.e. ETs-
1, -2, -3 (1, 2). ETs are generated from the 38-amino
acid precursors, big ETs, through cleavage of the
Trp21-Val22 bond via the action of a membrane-
bound metalloprotease, ET converting enzyme
(ECE)-1 and -2 (3, 4). ETs are produced not only
by endothelial cells, but also in various tissues, in
particular prepro-ET-1 mRNA is expressed widely
in vascular endothelial cells, heart, brain, kidney,
lung, uterus, and placenta (5). The circulating blood
concentrations of ET-1 in healthy subjects have
been reported to be very low as 13 pg/ml (6, 7),
a finding suggesting exertion of their effects in a
paracrine or autocrine manner in the local areas.
ET-1 is biologically active and acts as modulators
of vasoconstriction, neurotransmission, cell prolifera-
tion, and hormone/cytokine production (8, 9). Thus,
ET-1 is thought to play an important role in the
regulation of circulatory system. The plasma ET-1
concentration was reported to be mildly elevated in
patients with hyperlipidemia or atherosclerotic dis-
ease (10-12).
In our previous study, in addition to well-known
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ETs, ET-1(1-31) is generated following the specific
cleavage of precursor big ET-1(1-38) at the Tyr31-
Gly32 bond by human mast cell-derived chymase
(13). Furthermore, it is an intermediate peptide
which is transformed to ET-1 by the neutral en-
dopeptidase (NEP) (14, 15). This ET intermediate
peptide may be of clinical importance in conditions
such as ischemic heart disease and acute coronary
syndromes where there is increased generation of
big ET-1(1-38) (16) and increased protease activi-
ties including chymase in tissues (17). In the fol-
lowing text, we use expression of ET-1(1-21) for
mature ET-1 to avoid confusion with ET-1(1-31).
However, the pathophysiological and physiological
role of ET-1(1-31) remains unclear. In this study,
to investigate the relevance of pathophysiology and
the concentration of ET-1(1-31) in vivo , we have
used specific sandwich-type, enzyme-linked im-
munosorbent assay (ELISA) to measure the plasma
concentration of ET-1(1-31) in healthy volunteers
and patients with myocardial infarction with percu-
taneous transluminal coronary angioplasty (PTCA).
In addition, we determined ET-1(1-31) concentra-
tion in heart tissue of patients with acute myocar-
dial infarction.
METHODS AND MATERIALS
Blood Sampling
The patients (age ; 6311 years old, 9 males and
3 females) studied were the hospitalized patients
with acute myocardial infarction with PTCA in
Tokushima Red Cross Hospital, Tokushima prefec-
ture, Japan. Blood samples of patients with acute
myocardial infarction were collected before and the
1, 2, 3, and 7th day after the PTCA. Blood samples
were obtained also from healthy volunteers (age ;
3313 years old, 6 males and 5 females) after an
overnight fast.
The blood samples were collected and immedi-
ately transferred to a tube containing proteinase in-
hibitor (aprotinin 300 μl, EDTA-2Na 20 mg), placed
on ice for 10 minutes and plasma was immediately
separated by centrifugation (3,000 rpm for 10 min-
utes at 4). Plasma samples were stored at -25
until analysis.
The study was undertaken with the approval of
the research ethics committee of Tokushima Red
Cross Hospital and in accordance with the Declara-
tion of Helsinki. Informed consent was obtained
from all healthy volunteers and patients.
Human plasma sample preparation
Extraction of ET-1(1-31) in plasma was per-
formed by absorption on Sep-Pak C18 cartridges
(Waters, Milford. MA. U.S.A.). Sep-Pak C18 car-
tridges were preactivated by successive washes with
5 ml of acetic acid-ethanol (4% acetic acid, ethanol),
5 ml of methanol, 5 ml of Milli Q water and 5 ml of
4% acetic acid. Then 1 ml aliquot of the plasma sam-
ple was acidified with 3 ml of 4% acetic acid and ap-
plied to the column. The columns were washed with
1 ml of 4% acetic acid and 10 ml of Milli Q water,
and the absorbed materials were eluted with 4 ml
of acetic acid-ethanol. The eluate was dried under
a continuous stream of nitrogen and the dried elu-
ates were reconstituted with 1 ml ethanol, which
were dried again for later analysis. The dried elu-
ates were redissolved in 250 μl of buffer A (0.02 M
phosphate buffer, pH 7.0, 0.2% BSA, 0.4 M NaCl, 2
mM EDTA) and sonicated for 10 minutes. The re-
constituted plasma samples were centrifuged at
12,000 rpm for 5 minutes in 4, which was taken
for analysis.
A 1 ml of plasma was acidified with 250 μl 2 N
HCl kept for 30 minutes, neutralized by 250 μl 2 N
NaOH and then centrifuged at 10,000 rpm for 5 min-
utes. PBS(-) solution of twice volume was added to
them after supernatant was loaded onto the column.
The dissolved samples were applied to the ET-affin-
ity column (IBL, Fujigaoka, Japan). The columns
were washed with 20 ml of PBS(-), 5 ml of distilled
water and the absorbed materials were eluted with
30% acetonitrile / 0.05% TFA. The eluate was dried
using a SpeedVac concentrator and redissolved in
250 μl of buffer A subjected the sandwich-ELISA.
Heart ET-1(1-31) concentration in a patient with
myocardial infarction
The autopsy cardiac tissues from a patient with
myocardial infarction were added to the cold 1 M
acetic acid, pepstatin (10 ng/ml) solution about 10
times the amount of an organization. The samples
were homogenized using Polytron homogenizer in
ice and heat-treated it for 10 minutes at 100. After
neutralized by 10 N NaOH, twice amounts of PBS(-)
of the sample was added, and centrifuged in 4,
20,000 rpm for 30 minutes. The supernatant after
centrifugality was purified by using affinity column,
and it was considered as the sample for sandwich-
ELISA.
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Sandwich-ELISA
An EIA microtiter plate was coated with anti-
ET mouse monoclonal antibody (1 μg/ml) (IBL,
Fujioka, Japan) in 50 mmol/l carbonate buffer (50
μg/well), pH 9.6 at 4for overnight. The antigen
was dissolved in buffer A (0.02 M phosphate buffer,
pH 7.0 containing 0.2% BSA and 0.4 M NaCl and 2
mM EDTA) and mixed with biotinylation affinity pu-
rified ET-1(1-31) antibody (4.8 μg/ml) in buffer B
(buffer A containing 10% skim milk) at the ratio of
1 : 1. The plates were allowed to stand at 4for
overnight and after washing well by T-TBS buffer,
and were blocked with 150 μl of blocking buffer
(TBS containing 10% skim milk and 0.1% NaN3) at
4for more than 6 hours. The wells were washed
with T-TBS buffer, and then 50 μl /well of the sam-
ple were added to the plate at 4overnight. Bioti-
nylated anti-ET-1(1-31) antibody (0.5 μg/ml, in 10
nmol/l phosphate buffer, containing 140 mmol/l
NaCl and 1% BSA, pH 7.2) was added to each well
and incubated at 4for 24 hours. After washing
each well with T-TBS, the bound enzyme was re-
acted with En Vision+, peroxidase, anti-rabbit con-
jugated (2 μg/ml) (DAKO). Peroxidase activity was
measured by using 3,3’,5,5’ -tetramethyl benzene di-
hydrochloride (Sigma, USA) as a substrate at 37,
and the reactions were stopped by the addition of 2
M H2SO4 (50 μl/well). The density was determined
by analysis of absorbance at 450 nm.
The cross-reactivity with a number of related com-
pounds, such as ETs, vasopressin and bradykinin,
was less than 0.01%.
RESULTS
Construction of the sandwich-ELISA for ET-1(1-
31)
ET-1(1-31) peptide is prepared to the concentra-
tions of 1, 5, 10, 20, 40, and 60 pg/well as an anti-
gen, and the standard curve was established us-
ing the sandwich-ELISA. The standard curve with
nearly a straight line could be obtained in a concen-
tration dependent manner up to at least 1 pg/well,
suggesting that we can measure quantitatively ET-
1(1-31) up to 1 pg/well.
Establishment of the sampling method of ET-1(1-
31) in blood
We added 20 ng/ml ET-1(1-31) into the serum of
a pig, and collected the ET-1(1-31)-added sample.
We extracted ET-1(1-31) by using Sep-Pak C18
cartridges and affinity column. Then, we compared
the recovery rate by these two methods. The sand-
wich-ELISA was performed by using ET-1(1-31)
peptide (20 ng/ml) and the sample refined using
each column as an antigen. The recovery rate of
ET-1(1-31) peptide was the ratio with the measured
value of the antigen obtained by each column. The
recovery rate of ET-1(1-31) peptide obtained by
the refining methods by Sep-Pak C18 cartridges
was 12.9%, but affinity column improved the recov-
ery rate very much, i.e., 99.2%. These results sug-
gest that the refining process using affinity column
was suitable for a sampling process of ET-1(1-31).
Therefore, in the following experiments, the sample
was prepared by affinity column.
Plasma concentration of ET-1(1-31) in healthy vol-
unteers
The mean plasma concentrations of ET-1(1-31)
in 11 healthy volunteers (6 men, 5 women, average
age 3313 years old) with the sandwich-ELISA,
was 24.85.2 pg/ml. The mean value of male was
25.53.1 pg/ml (average ages 3212 years old),
and that of woman was 23.97.3 pg/ml (average
ages 3415 years old). Thus, there was no signifi-
cant difference by sex in plasma concentrations of
ET-1(1-31). There was no significant difference in
plasma concentrations of ET-1(1-31) by ages either,
i.e., those of 50’s was 28.14.8 pg/ml (n=3), and
those of 20’s 23.15.3 pg/ml (n=7).
Plasma concentrations of ET-1(1-31) and ET-1(1-
21) in patients with acute myocardial infarction
Fig. 1 shows the time course of plasma concen-
trations of ET-1(1-31) and ET-1(1-21) after acute
myocardial infarction. Blood levels of ET-1(1-21)
showed the normal value on admission, and after
PTCA plasma concentrations rose promptly followed
by rapid falling. Similarly with that of ET-1(1-21),
the concentrations of ET-1(1-31) also showed rapid
increase after PTCA and then decrease. The plasma
concentration of ET-1(1-31) showed its peak at the
2nd day after the onset of myocardial infarction and
remained at higher levels up to 7 days after the
onset. Moreover, the plasma concentration of ET-1
(1-31) always showed the 46 times higher value
compared with ET-1(1-21) throughout the course.
The concentrations of ET-1(1-31) in patients with
myocardial infarction were 38 fold higher than
that of healthy controls. Fig. 2 shows time course of
the concentrations of ET-1(1-31) of each of the 12
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patients with acute myocardial infarction with PTCA.
Although the concentration and time courses were
various, there was a tendency to show dual peaks.
These results suggest that ET-1(1-31) may play
some roles in acute myocardial infarction and its
healing process.
Comparison between blood concentration of ET-
1(1-31) and biochemical profile in the patients with
myocardial infarction
As there were two patterns of ET-1(1-31) eleva-
tions, we compared the time courses of other pa-
rameters. Fig. 3 shows time course of the enzyme
activity of CK, AST, LDH, and ET-1(1-21) within
ET-1(1-31) concentrations in 3 patients. All 3 pa-
tients showed that CK and AST rose markedly on
the next day of PTCA, and it decreased promptly af-
ter the peak. LDH responded slowly compared to
CK and AST, and maintained higher concentrations
long time which was similar in time course with that
of ET-1(1-31). In panel A, peak CK was 1365 IU/l
suggesting the size of infarction was small. In this
patient, ET-1(1-31) gradually decreased to normal
values without second elevation and ET-1(1-31)
showed a similar change with CK and AST. In pan-
els B and C, in which the peak CK was higher than
that of panel A, higher ET-1(1-31) levels was main-
tained for many days after the first peak, which was
Fig. 2 The concentration of ET-1(1-31) in 12 patients with acute myocardial infarction after PTCA. The first peak of ET-1(1-31) levels
appeared on the 2nd day after PTCA. Few patients showed gradual decrease after this peak, but most of the patients showed sus-
tained elevation after the first peak after 3rd day.
Fig. 1 Time course of the plasma concentrations of ET-1(1-31) and ET-1(1-21) in patients with acute myocardial infarction with
PTCA measured by the sandwich-ELISA. Note that concentrations of ET-1(1-31) are higher than ET-1(1-21). ET-1(1-31) showed
second peak and its elevation lasted longer than that of ET-1(1-21).
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different in time course from that of ET-1(1-21),
suggesting that ET-1(1-31) showed biphasic eleva-
tion in patients with larger infarction.
The ET-1(1-31) concentration of tissues in a myo-
cardial infarction patient
ET-1(1-31) concentration of the heart (n=5) of
the patient who died of myocardial infarction was
measured with sandwich-ELISA, and the average
value of ET-1(1-31) quantity per organization pro-
tein 1 mg was calculated. ET-1(1-31) concentrations
of the heart with myocardial infarction showed ex-
tremely high values, i.e., 12729.82617.7 pg/mg
protein.
DISCUSSION
ET-1(1-31) is produced by several proteases in
inflammatory sites and has similar action with ET-
1(1-21) on vasoconstriction, neurotransmission, cell
proliferation, and hormone/cytokine production.
Using a newly developed sandwich-type enzyme im-
munoassay for ET-1(1-31) with high sensitivity and
specificity, we found that ET-1(1-31) exists at low
concentrations in healthy volunteers, and was higher
in patients with acute myocardial infarction than that
of healthy volunteers. In addition, its elevation lasted
longer, i.e. at least until 7 days after the onset, sug-
gesting that ET-1(1-31) might have some patho-
physiological function after myocardial infarction.
In the previous reports (6, 7, 18-20), the plasma
concentrations of big ET-1 and ET-1(1-21) ana-
lyzed by EIAs and radioimmunoassay was about 5.5
pg/ml and 1.5 pg/ml in healthy subjects, respec-
tively. As for the plasma concentration of ET-1(1-
31) in healthy subjects, Suzuki et al. (21) reported
the value of 19.245.70 pg/ml, and Leslie et al.
1.10.1 pg/ml (22). In the present study, it was
24.85.2 pg/ml, which is slightly higher than those
of Suzuki et al. but much higher than those of Leslie
et al. . The discrepancy might be partly due to the
difference of the column used for the purification of
the antigen. In the present study, we established a
Fig. 3 The representative time course of ET-1(1-31), ET-1(1-21), the enzyme activity of CK, AST, and LDH changes in 3 patients with
myocardial infarction. In small infarction (panel A), ET-1(1-21) and ET-1(31) decreased after the peak. In other 2 cases (Panels B and
C), in which peak CK was higher, ET-1(1-31) showed sustained elevation after the first peak.
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sandwich-ELISA that was purified antigen by ETs
affinity column. The recovery rate of this affinity col-
umn was higher than Sep-Pak C18 cartridges that
have been used in the previous studies. Thus, the
differences in recovery of ETs might affect the meas-
urements of the plasma concentration of ET-1(1-
31).
The plasma concentration of ET-1(1-31) in nor-
mal subjects, several times higher than those re-
ported in ET-1(1-21) or big ET-1, suggesting that
ET-1(1-31) may have some pathophysiological func-
tion as it has similar action with ET-1(1-21), though
slightly weaker than that of ET-1(1-21) (23-25). For
gender differences, Miyauchi et al. have reported
that men’s plasma concentration is slightly higher
than women’s (26). Komatsumoto et al. (27) re-
ported that there is a positive correlation between
ET-1 and aging. In the present study, we found no
significant difference between different genders or
ages.
There have been no studies of circulating ET-1
(1-31) in pathological conditions, although there are
many studies of ET-1(1-21). Miyauchi et al. (14)
and others (12, 16, 28-30) has been reported that
plasma concentration of ET-1(1-21) in patients with
acute myocardial infarction significantly rose after
an attack and gradually decreased, and returned to
the normal level in approximately two weeks. Fur-
thermore, plasma concentrations of ET-1(1-21) rose
after laparotomy and thoracotomy (31), coronary ar-
tery bypass grafting (32), and PTCA (33, 34), and
these values were gradually normalized after sur-
gery. In the present study, the peak values of CK,
AST and those of first peak of ET-1(1-31) were ob-
served at the same time after PTCA. In addition,
ET-1(1-31) maintained higher concentration for a
longer period, suggesting that ET-1(1-31) might
relate to some pathophysiological function after myo-
cardial infarction. The early peak of ETs as well as
AST and CK seen after PTCA is due to reperfusion
of damaged areas and washout by reperfusion. It is
thought that the slightly higher concentrations at
late phase might be due to participating in remod-
eling of blood vessel and the myocardium, as ET-1
(1-31) also has functions similar to ET-1(1-21), al-
though its function is weaker than that of ET-1(1-
21).
It was considered that increased concentrations
of circulating ET-1(1-21) are the result of produc-
tion and release of ET-1(1-21). TGF-β and throm-
bin from platelets aggregated to the site of injury
stimulate ETs production, and leakage or release of
ET-1(1-21) from injured endothelial cells by in-
farction or hemorrhage. In these areas, proteases
are secreted abundantly, which cleave big ET into
various forms of ETs, including ET-1(1-21) and ET-
1(1-31). In agreement with these studies, we also
found that the tissue concentration of ET-1(1-31)
was extremely high in patients who died of myo-
cardial infarction. ET-1(1-31) is the major bioactive
peptide among the ET derivatives in human neutro-
phils (35). Furthermore, ET-1(1-31) possessed che-
motactic activities toward neutrophils and monocytes
(36) and stimulated eosinophil recruitment (37).
Similarly with our study, ET-1(1-31) is more re-
markable in the arteriosclerosis lesion than conven-
tional ET-1(1-21), and strong expression is recog-
nized with the inflammatory blood cells, suggesting
that ET-1(1-31) participates in the development of
the arteriosclerosis and myocardial remodeling with
progress of inflammation (38). In addition, ET-1(1-
31) is an intermediate peptide, which is then readily
transformed to more potent ET-1(1-21) by the NEP,
suggesting that ET-1(1-31) also plays an important
role in providing a more portent peptide, ET-1(1-
21).
Increase of the plasma concentration of ET-1(1-
21) in heart failure correlates with the severity of
heart failure, which has been reported to be useful in
determining the prognosis (39, 40). It was thought
that rise of ET-1(1-21) concentrations in the organic
damages of vascular endothelium reflects the degree
of vascular disease and the associated with remod-
eling. ET-1(1-31) equally, contributes to determine
the severity of the conditions as well as diagnostic
significance of a particular disease, suggesting that
ET-1(1-31) might be an important marker for re-
modeling in postmyocardial infarction.
ET-1(1-31) is abundant not only in plasma but
also in inflammatory lesions suggesting that this
peptide plays in various pathological conditions.
More recently, ET-1 receptor blockers, which also
block ET-1(1-31) effects (23-25), became available
in clinical medicine including pulmonary hyper-
tension and myocardial infarction (41). The use of
these drugs to inhibit ET-1(1-31) after myocardial
infarction will help understanding of mechanism of
ET-1(1-31) by future studies.
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